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Abstract
Psoriasis is a multifactorial inflammatory skin disease characterized by increased proliferation of keratinocytes, activation of
immune cells and susceptibility to metabolic syndrome. Systems biology approach makes it possible to reveal novel
important factors in the pathogenesis of the disease. Protein-protein, protein-DNA, merged (containing both protein-
protein and protein-DNA interactions) and chemical-protein interaction networks were constructed consisting of
differentially expressed genes (DEG) between lesional and non-lesional skin samples of psoriatic patients and/or the
encoded proteins. DEGs were determined by microarray meta-analysis using MetaOMICS package. We used STRING for
protein-protein, CisRED for protein-DNA and STITCH for chemical-protein interaction network construction. General
network-, cluster- and motif-analysis were carried out in each network. Many DEG-coded proteins (CCNA2, FYN, PIK3R1,
CTGF, F3) and transcription factors (AR, TFDP1, MEF2A, MECOM) were identified as central nodes, suggesting their potential
role in psoriasis pathogenesis. CCNA2, TFDP1 and MECOM might play role in the hyperproliferation of keratinocytes,
whereas FYN may be involved in the disturbed immunity in psoriasis. AR can be an important link between inflammation
and insulin resistance, while MEF2A has role in insulin signaling. A controller sub-network was constructed from interlinked
positive feedback loops that with the capability to maintain psoriatic lesional phenotype. Analysis of chemical-protein
interaction networks detected 34 drugs with previously confirmed disease-modifying effects, 23 drugs with some
experimental evidences, and 21 drugs with case reports suggesting their positive or negative effects. In addition, 99
unpublished drug candidates were also found, that might serve future treatments for psoriasis.
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Introduction
Psoriasis is a multifactorial inflammatory skin disease. A recent
systematic review reported a prevalence from 0% (Taiwan) to
2.1% (Italy) in children and from 0.91% (United States) to 8.5%
(Norway) in adults.[1] Genetic predisposition and environmental
factors are both important in disease etiology. Several genome-
wide association studies have been carried out and until now 36
susceptibility loci have been identified.[2] Environmental triggers
are also reported such as drugs, smoking, mental stress, skin injury,
Streptococcal infection, hormonal changes etc.[3] Psoriasis is an
immune-mediated disease. Important immune cells and cytokines
have been identified in disease pathogenesis such as IL6, IL17A,
TNF etc.[4] Autoimmune basis for chronic inflammation is
supposed, although no consistent antigen has been found. Patients
with psoriasis have higher risk for metabolic syndrome, and risk
increases with disease severity. Both diseases have immunological
basis with common cytokines and genetic risk loci like
CDKAL1.[5] Keratinocyte hyperproliferation is present in le-
sional phenotype and is responsible for scale formation. Kerati-
nocyte differentiation markers like keratin 1 and keratin 10 are
downregulated and parakeratosis (keratinocytes with nuclei in the
stratum granulosum) is also present.[3]
Psoriasis is one of the most studied skin diseases. By now more
than 34000 hits are available in PubMed for the keyword
‘‘psoriasis’’ and the number is increasing. No spontaneous
psoriasis-like skin disease is known in animals. Induced mouse
models are available which are similar, but not the same as
psoriasis in human.[6] Therefore drug discovery is difficult in such
models what makes in silico analysis more essential. ‘‘Omics’’ data
gives the opportunity to examine the disease with systems biology
approach.
Stationary changes in gene expression are responsible for fixing
phenotypes such as lesional skin areas in psoriasis. Several
microarray studies have been carried out to characterize gene
expression in healthy and psoriatic skin samples (Table 1).
Microarray meta-analysis gives the opportunity to evade biolog-
ical, regional, and study design-caused variation between stud-
ies.[7] Network analysis is a novel and highly developing area of
systems biology. Considering gene expression data it is possible to
explain alterations in intracellular processes with the analysis of
protein-protein and protein-DNA (or gene regulatory) interaction
networks. These networks consist of proteins and/or regulated
genes as nodes and undirected or directed edges between them.
Network centralities like degree or stress are suitable for ranking
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nodes. Total edge number belong to one node equals its degree in
undirected networks. Nodes have in- and out-degrees based on
edge directions in directed networks. Degree distribution follows a
scale-free power law distribution in biological networks. This fact
indicates that highly connected vertices have a large chance of
occurring. Nodes with highest degree are called hubs and are
essential in network stability.[8] Stress centrality indicates the
number of shortest paths (from all shortest paths between any two
nodes in the network) passing through the given node thus the
capability of a protein for holding together communicating
nodes.[9] Interconnecting nodes make up network motifs. Several,
such as feed-forward or bifan motif are significantly enriched in
biological networks compared to random networks. These
elements have important role in network dynamics.[10]
We hypothesized that it could be possible to find novel elements
of psoriasis pathogenesis with detailed analysis of precisely
constructed networks. Network motif enrichment caused by
changes in gene expression could have important role in disease
development and sustainment. It could be also possible to detect
potential drug candidates by analyzing chemical–protein net-
works. Thus our goal was to construct reliable but yet detailed
protein-protein, protein-DNA, merged (containing both protein-
protein and protein-DNA interactions) and chemical-protein
interaction networks consisting of differentially expressed genes
(DEG) between lesional and non-lesional skin samples and/or the
coded proteins. Detailed analysis of these networks could help us
to reveal novel players in disease pathomechanism and to identify
network motifs and sub-networks with the ability to sustain lesional
phenotype.
Methods
Microarray Meta-analysis
Six microarray studies examining lesional and non-lesional skin
biopsy samples of psoriatic patients were found in Gene
Expression Omnibus (GEO) (Table 1). ‘‘Minimum Information
About a Microarray Experiment’’ (MIAME) was available for
each study. Only non-lesional and lesional samples from affected
individuals were used for analysis, samples from healthy people
were excluded. Raw.CEL files were downloaded and quality of
each sample was assessed with the R package arrayQuality-
Metrics.[11] This package defines sample quality with 5 different
methods and generates plots for outlier detection. A sample was
excluded if it was obviously an outlier in at least 1 measure or had
borderline values in at least 2 measures (analysis results are in
Dataset S1 compressed file; outliers and argument of exclusion is
listed in Table S1). Raw data normalization of remaining samples
was carried out with the R package Easy Microarray data Analysis
(EMA).[12] GCRMA normalization method was used and probe
sets with expression level below 3.5 were discarded. Probe set with
the highest interquartile range (IQR) was chosen for common
HUGO Gene Nomenclature Committee (HGNC) gene identifiers.
Original findings were confirmed with published statistics. For this
EMA was used after GCRMA normalization. More DEGs were
found in some cases, which might be caused by the pre-filtering
process with arrayQualityMetrics (Table S2). The R package
MetaQC was used for filtering out low quality studies.[13] The
fifty most prevalent gene set were chosen with the software Gene
Set Enrichment Analysis (GSEA) and used for external quality
control (EQC) score calculation.[14] GSEA was carried out for
each study with the following settings: 1000 permutations;
minimum set size was 5 and the gene set database was
c2.all.4.0.symbols. The resultant study-level p values of a gene
set were combined with Fisher’s combined probability test. The
fifty gene sets with the lowest meta-analysis p value were chosen as
input for EQC score calculation. C2.all.4.0.symbols gene set
database was chosen as input for consistency quality control
(CQCp) value calculation. GSEA input expression matrices
contained gene IDs that were present in all studies after EMA
filtering. MetaDE package was used to determine DEGs in lesional
samples compared to non-lesional ones.[15] DEG p value in
individual studies was calculated by two sample T test with
unequal variances. Fisher’s combined probability test was chosen
for meta-analysis statistical method.[16] Fold change of gene
expression was given by the ratio between geometrical means of
gene expression in lesional and non-lesional samples.[17] Genes
with false discovery rate (FDR) less than 0.001 and with fold
change higher than 1.5 or less than 21.5 were accepted as DEGs.
Table 1. Study information and QC measure summary.
Study MIAME GEO ID Platform/Chip NL L IQC EQC CQCg CQCp AQCg AQCp Rank
1 Gudjonsson et
al.[110]
Available GSE13355 GPL570/Affymetrix
HU133 Plus 2.0
54 53 4.18 4 307.65 307.65 95.2 292.19 2.17
2 Yao et al.[111] Available GSE14905 GPL570/Affymetrix
HU133 Plus 2.0
27 32 5.58 4 307.65 307.65 81.32 185.34 2.67
3 Zaba et al.[112] Available GSE11903 GPL571/Affymetrix
HU133A 2.0
15 12 7.34 3 307.65 307.65 79.24 260.95 2.75
4 Suarez-Farinas
et al.[113]
Available GSE30999 GPL570/Affymetrix
HU133 Plus 2.0
79 80 0.86* 4 307.65 307.65 33 193.93 3.67
5 Reischl et
al.[114]
Available GSE6710 GPL96/Affymetrix
HU133A
12 12 2.7 4 307.65 271.23 40.3 118.68 3.92
6 Johnson-Huang
et al.[115]
Available GSE30768 GPL571/Affymetrix
HU133A 2.0
1 4 Excluded by Array Quality Metrics package
MIAME information was available for all study Studies were downloaded from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). All studies were carried
out on Affymetrix platforms. Lesional and Non-Lesional sample count is shown. Stars in table indicate non-statistical significance of QC measures. Study no 6 was
already excluded by sample filtering by arrayQualityMetrics. Other studies had high quality and no outlier study was present. IQC: Internal Quality index, EQC: External
Quality index, CQCg and CQCp: Consistency Quality Control indexes, AQCg and AQCp: Accuracy Quality Control indexes, NL: non-lesional sample count, L: lesional
sample count.
doi:10.1371/journal.pone.0080751.t001
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Construction of protein-protein, protein-DNA and
chemical-protein interaction networks
STRING database 9.0 was used as resource for protein-protein
interactions (PPI).[18] Both directed and undirected networks
were created by selecting all interactions between DEG – coded
proteins in downloaded raw data. Interaction confidence score
cutoff was 900 (‘‘highest confidence’’ group) in case of undirected
and 800 (containing a part of ‘‘high confidence’’ and all ‘‘highest
confidence’’ interactions) in case of directed interactions. Only
directed interactions with ‘‘activation’’ or ‘‘ptmod’’ actions were
used. Chemical-protein interactions between potential drugs,
intra- and extracellular compounds and DEG-coded proteins
were collected from STITCH database 3.1.[19] The way of
interaction confidence score calculation is the same in this
database as in STRING thus interactions with the described
confidence score cutoff values were selected for network construc-
tion. Protein-DNA interaction (PDI) network consisting of DEGs
and DEG-coded transcription factors (TF) was created using cis-
Regulatory Element Database (CisRED).[20] Regulatory element
motifs with pv0:001 were collected from DEG promoter regions.
Motifs were coupled with TFs or TF complexes using TRANS-
FAC and JASPAR databases.[21,22] Motifs without respective
TFs were excluded. Merged DEG-derived network containing PPI
and PDI interactions and a network containing only DEG-coded
TFs were also generated. Complete PPI, PDI, merged, TF-TF and
chemical-protein interaction networks were created for controls
using all available interactions in databases with the same
statistical threshold as in DEG-derived network construction.
General network analysis, identification of central nodes
and motif detection
General network analysis and node centrality value calculation
were carried out with NetworkAnalyzer Cytoscape plugin.[23]
Isolated nodes and node groups (without connection with the main
PPI network) were deleted from graph in order to evade false
results. Curve fitting on node degree and stress value distributions
was done with MATLAB Curve Fitting Tool (MATLAB R2012b,
The Mathworks Inc., Natick, MA). Curve of power law
distribution was assessed with Trust-Region algorithm. Goodness
of fitting was assessed by R-square and corrected R-square values
which prove power law distribution of these node centralities
(Table 2). As power law distribution is asymmetric with a long tail,
nodes with centralities above average cannot be assessed using
arithmetic mean. A variable with a power-law distribution has a
probability P kð Þ of taking a value k following the function
P kð Þ*Ck{c, where C is constant. First moment (mean value) of a
power-law distributed quantity equals:
SkT~
c{1
c{2
kmin; (cw2)
Second moment (variance) of a power-law distributed quantity
equals:
Sk2T~
c{1
c{3
k2min; (cw3)
The sum of first and second moment (mean value and variance)
was used as cutoff for centralities with distribution exponent cw3.
Expression of variance becomes infinite, when cƒ3, thus only first
moment (mean value) was used as cutoff for centralities with
distribution exponent2vcv3. [24] Expression of mean value
becomes infinite, if cƒ2. In this case weighted mean was used to
assess cutoff with the following formula:
SkT~
Pn
i~1
ki
1
Ck
{c
i
Pn
i~1
1
Ck
{c
i
As bidirectional connections are available in undirected PPI
network, stress centrality is independent from edge directions thus
both degree and stress had to be above cutoff for central protein
selection. As directed networks contain unidirectional interactions,
low stress values (i. e. low number of shortest paths cross through
the node) can be caused by the dominance of incoming (in-degree)
or outgoing (out-degree) interactions. Important nodes with high
in-degree or out-degree can still have low stress centrality thus
either out-degree or in-degree or stress had to be above cutoff in
directed PPI network. As TFs have mainly outgoing interactions,
out-degree was used for TF prioritization. Similarly to PPI
networks degree and stress had to be above cutoff in undirected
chemical - protein interaction network. Drugs with more targets in
DEG-derived PPI-networks may have bigger disease modifying
effect thus out-degree had to be above cutoff in directed chemical
– protein interaction network for drug prioritization (Table 2).
NetMODE software was used for network motif statistical
analysis. Frequency of 3 or 4 node motifs in DEG-derived and
complete control networks were compared with 1000 random
graphs. Local constant switching mode was used for edge switching
method during random network generation. NetMODE p value
indicates the number of random networks in which a motif
occurred more often than in the input network, divided by total
number of random networks. pv0:05 was used as cutoff.[25]
Respective sub-networks of enriched motifs were identified with
NetMatch Cytoscape plugin.[26] jActiveModules and Cluster-
ONE were used for network module and protein complex
detection. ClusterONE analysis was carried out with minimum
cluster size of 3 with unweighted edges and default advanced
parameters. jActiveModules considers gene expression for module
search. Input gene expression values have to be between 0 and 1
so normalized expression values got with EMA were scaled
between these numbers.[27,28] Functional description of node
groups was done with BinGO (‘‘Biological function’’ GO terms
were selected, FDR,0.001 was used for term enrichment).[29]
Results
Detection of DEGs with microarray meta-analysis
In order to get reliable data about gene expression in lesional
psoriatic skin samples microarray meta-analysis was carried out.
The study by Johnson-Huang et al. was already excluded after
sample quality analysis with arrayQualityMetrics package, because
at least two samples from one phenotype group are needed for
MetaQC analysis and only one non-lesional sample remained after
sample filtering. The overall quality of each study was assessed by
MetaQC.[13] The software calculated six quality control (QC)
measures then created principal component analysis (PCA) biplot
and standardized mean rank summary (SMR) score to help in the
identification of problematic studies. It was described by authors,
that if a study is on the opposite side of arrows in the PCA biplot
and has large SMR scores, it’s strongly suggested to be excluded
from meta-analysis. In contrary, if a study is on the same side of
arrows in the PCA biplot and has small SMR scores, it should be
Network Analysis in Psoriasis
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included. All five studies were defined as usable based on quality
values (Table 1, Figure 1). DEGs were identified by MetaDE.[15]
2307 upregulated and 3056 downregulated genes were found in
lesional skin samples compared to non-lesional ones (Table S3).
The relatively high number of DEGs can be the result of filtering
out low quality samples, which could increase variance and using
lower fold change cutoff values than in original studies. DEGs
were used for network construction.
General Network analysis
Undirected and directed PPI networks with DEG – coded
proteins, directed PDI networks with DEG – coded TFs and
regulated DEGs and merged directed networks containing both
PPIs and PDIs were created. A TF-TF network consisting of
DEG-coded TFs was also generated. The Cytoscape plugin
NetworkAnalyzer calculated main network properties for both
DEG-derived and control complete networks (Table 3). DEG –
derived networks had higher diameter (i. e. the length of the
longest shortest path in the network) and average shortest path
length than control full networks. This may be caused by the
Table 2. Results of node centrality analysis.
Network Centrality Curve Cutoff R-square Adjusted R-square
PPI Undirected Degree 0.8555xˆ-1.649 27.21 0.9957 0.9956
Stress 47.1xˆ-0.8034 427072.25 0.9795 0.9793
PPI Directed In-Degree 0.5925xˆ-1.808 5.100152 0.9969 0.9968
Out-Degree 0.5462xˆ-1.759 23.493461 0.9983 0.9983
Stress 15.34xˆ-0.961 8504.103 0.8753 0.8748
PDI Out-Degree 13280xˆ-1.367 287.20865 0.9252 0.9002
CPI Undirected Degree 0.8314xˆ-3.168 14.761 1 1
Stress 2.41e14ˆ-2.432 6.63 0.9811 0.9811
CPI Directed Out-Degree 0.7859xˆ-2.132 8.5757576 1 1
Distribution of node centrality values were assessed by curve fitting. Curve equations, goodness of fit (R-square and adjusted R-square) and the resultant cutoff values
are shown. CPI: chemical – protein interaction network.
doi:10.1371/journal.pone.0080751.t002
Figure 1. PCA biplot numbers on PCA biplot represents studies in Table 1. Study number placed opposite to quality measure axes are of
low quality and should be excluded. No outlier study was detected.
doi:10.1371/journal.pone.0080751.g001
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inverse correlation of node degree and fold change.[30] Nodes
with lower fold change has higher degree. Genes with fold change
under cutoff are filtered out from DEG derived networks (between
red lines on Figure 2). The remaining nodes has smaller average
degree, therefore connectivity of the network is lower resulting in
higher diameter and average shortest path length value.
Determination of hubs in DEG-derived networks
Most important nodes of DEG-derived networks were deter-
mined using degree and/or stress centralities (Table 2, full list of
nodes and centralities is in Table S4). Numerous already published
psoriasis-associated protein-coding genes were found (Table 4).
CCNA2, FYN and PIK3R1 proteins are present in top rated hubs
in undirected PPI network and are yet unpublished in association
with the disease. CCNA2 have role in mitosis regulation.[31] FYN
is important in interferon gamma (IFN gamma) signaling, while
PIK3R1 is important in insulin-stimulated glucose uptake.[32,33]
FYN could be found in jActiveModules cluster with the 2nd highest
score while PIK3R1 were found in cluster with the 3rd highest
score (Figure S1, S2). Taking account BinGO results these clusters
Figure 2. Degree-Fold Change relationship. Nodes with higher degree has lower fold change of gene expression in all network types. Genes
between red lines have higher average degree and are filtered out from network analysis. Remaining nodes in DEG-derived networks have lower
average degree and connectivity.
doi:10.1371/journal.pone.0080751.g002
Table 3. Results of general network analysis.
Network Nodes Edges Diameter
Average
shortest path
PPI Undirected 1614 (9412) 5156 (55039) 14 (12) 4.79 (4.45)
PPI Directed 464 (4040) 815 (13377) 14 (12) 5.26 (4.35)
PDI 2840 (15839) 6398 (123210) 10 (7) 3.69 (3.029)
DEG derived and control networks has similar attributes, but average shortest
path length and network diameter is lower in DEG derived networks, which can
be explained by lower connectivity (Figure 2). Values for control networks are in
brackets.
doi:10.1371/journal.pone.0080751.t003
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are responsible for signaling and for immune regulation as well
(Table S5). A highly connected chemokine-chemokine receptor
cluster was also found with ClusterONE analysis (Figure S3).
Central nodes in directed and undirected PPI networks showed
overlap (Table 4). CTGF is in top ranked proteins and yet not
associated with psoriasis. CTGF is responsible for fibrosis
downstream of TGFb signaling. Downregulation of CTGF by
psoriasis-associated cytokines INFc and TNFa is already pub-
lished.[34]
PDI network contained DEG-coded TFs and regulated DEGs
as nodes and directed edges pointing from the TFs to the regulated
genes. TFs were ranked using out-degree centrality. Androgen
receptor (AR) and TFDP1 were the highest ranked nodes. AR is a
TF, regulating genes that have immunological functions and role
in carbohydrate metabolism.[35,36] TFDP1 controls cell cycle
progression and is yet not associated with psoriasis.[37] BinGO
analysis of TFDP1-regulated genes prove its central role in cell
cycle activation (Table S5). MECOM and MEF2A are TFs above
centrality cutoff and yet not associated with psoriasis. MECOM
have role in cell proliferation and is associated with chronic
myeloid leukemia.[38] MEF2A is responsible for the insulin
dependent glucose transporter GLUT4 expression and is down-
regulated in insulin deficient diabetes mellitus.[39]
Motif analysis in DEG-derived networks
Motifs consisting of 3 or 4 nodes were analyzed in directed
DEG-derived and control networks as well (Table 5, Figure 3).
Analysis found motifs which were enriched in directed DEG-
derived but were absent in control networks or vice versa. Some
were already generally described in biological systems like
Table 4. Top rated nodes in DEG-derived networks.
PPI Undirected PPI Directed PDI
Name Fold change Name Fold change Name Fold change
IL8 67.31113193 IL8 67.31113193 TFDP1 4.612130627
CCNB1 11.13277565 BIRC5 9.309154577 MECOM 1.705869235
BIRC5 9.309154577 MMP1 7.446458555 AR 21.649992095
STAT1 9.038900879 SOD2 7.198087989 NF1 21.707954442
CCNA2 8.737535122 IL1B 4.293906976 MEF2A 21.738635445
CXCR4 5.109553129 STAT3 3.965626652
IL1B 4.293906976 MMP9 3.661047085
MAPK14 4.152927326 SOCS3 3.315643007
STAT3 3.965626652 HMOX1 3.207443671
MMP9 3.661047085 CCL2 2.896844503
LCK 3.609090653 BAX 1.9009731
AURKB 2.493884913 ICAM1 1.722246429
MAPK1 1.820524831 CD69 1.721780507
MYC 1.690987073 MYC 1.690987073
NFKB1 1.636019496 CD86 1.676295675
PCNA 1.623673041 CD28 1.640633244
CDKN1A 1.583889601 NFKB1 1.636019496
HDAC1 1.57828429 EGFR 21.607280925
CYP1A1 21.595883159 CTNNB1 21.648110677
EGFR 21.607280925 FN1 21.75413351
CREBBP 21.626480892 EDN1 21.836157927
CTNNB1 21.648110677 SP1 21.923552267
FN1 21.75413351 CTGF 22.037178621
FYN 21.849385591 NFATC1 22.187942784
SP1 21.923552267 IRS1 22.277490062
SMAD4 21.95145712 INS2IGF2 22.33005624
INS-IGF2 22.33005624 CCND1 22.341844947
CCND1 22.341844947 FOS 22.362430819
FOS 22.362430819 PPARG 22.556455049
PPARG 22.556455049 BCL2 22.632996792
BCL2 22.632996792 F3 23.835078706
PIK3R1 22.955639724 LEP 26.266827433
Central proteins with centrality value(s) above cutoff are listed. Fold change between gene expression in lesional and non-lesional samples are also shown. Proteins with
bold characters are yet non-published in terms of psoriasis.
doi:10.1371/journal.pone.0080751.t004
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convergent (no. 36), divergent (no. 6) and bifan (no. 204) motifs,
but yet non-examined ones were detected like motif no. 924 in
directed PPI networks, no. 332 in TF-TF networks and no. 6356
in merged networks etc. Cause of missing convergent, divergent
and bifan motifs in DEG derived directed PPI or PDI networks
compared to control was not investigated as uncertainty is present
about the role of these network motifs in biological systems.[10]
Identifying nodes making up motif no. 924 resulted in the high
occurrence of central proteins found before. These proteins were
associated with the immune system and carbohydrate metabolism.
Motif 332 is enriched in the TF network of lesional skin. This
motif is based on the TFDP1–AR reciprocal regulation. Impor-
tance of these TFs is already mentioned.
An interesting result of motif analysis is the enrichment of
feedback loops containing 3 nodes in merged networks compared
to separate ones and the enrichment of motif no. 6356 in DEG-
derived merged network compared to control. Motif no. 6356
consist of a positive feedback loop and all nodes of the loop are
controlled by another separated node like IL1B or AR.
Controller sub-network construction
Both lesional and non-lesional skin areas can be found on
patients at the same time. We wanted to highlight nodes which
may be important in the ‘‘all or none’’ switch in lesional skin areas
and sustain this phenotype for a long time. It has been argued that
hubs in intracellular regulatory networks are enriched with either
positive or negative regulatory links and cause much more positive
feedback loops than negative ones.[40] It is also proven that
positive feedback loops have fundamental role in maintaining
autoimmune and autoinflammatory disease states.[41] Enrich-
ment of motif no. 6356 consisting of a positive feedback loop with
all nodes controlled by a separated one also suggests central role of
positive feedback loops in lesional skin which may be activated by
important central proteins like AR or IL1B. This is published that
in biological systems interlinked slow and fast positive feedback
loops allow systems to convert graded inputs (like several
environmental and genetic factors in a psoriatic individual) into
decisive all or none outputs (like lesional skin phenotype).[42]
Transcriptional regulation needs time so we hypothesized that
slow positive feedback loops may consist of at least one gene
regulatory interaction. Fast loops may consist of only PPIs.
Transcriptional changes of nodes in these loops may be able to
sustain the ‘‘switched on’’ state.
In order to find most important slow and fast feedback loops
containing 2, 3 or 4 nodes, a merged PPI and PDI network was
constructed from proteins with centralities above cutoff value. All
feedback loops were identified with NetMatch. A positive feedback
loop was selected if and only if expression of all nodes changes in
the direction of sustaining or suppressing the activity of the loop
and ‘‘activation’’ or ‘‘inhibition’’ properties of all edges were
proven by publications. Expression of all nodes was downregulated
in two loops needed for carbohydrate metabolism: the INS-IGF2-
EDN1-LEP-INS-IGF2 and the LEP-PPARG-INS-IGF2-LEP
loop. The IL1B-NFKB1-CCL2-IL1B loop contained only upre-
gulated nodes and has role in inflammation (Figure 4). The
remaining loops contained inflammation and metabolism-related
Figure 3. Network motifs with 3 or 4 nodes. Analysis results of the respective motif can be found in Table 5.
doi:10.1371/journal.pone.0080751.g003
Table 5. Summary of network motif analysis.
PPI directed PDI PDI +PPI
Motif no. Psoriasis Full Psoriasis Full Psoriasis Full
6 (divergent) 0.705 0.031 0.168 0.974 0.908 0.952
36 (convergent) 0.997 0.972 0.826 0.023 0.083 0.045
38 (feed-forward) 0 0 0.073 0.978 0.941 0.998
98 (feedback) 0.329 0.242 0.518 0.233 0.064 0.046
204 (bifan) 0.255 0 0.483 0.082 0.872 0.041
332 0.958 0.162 0.042 (TF network) 0.838 (TF network) 0.41 0.067
924 0.007 0.292 N/A 0.305 0.794 0.17
6356 0.025 0.02 N/A 0.916 0.001 0.512
Numbers are p values of motif enrichment compared to 1000 random networks. Values with bold characters are below 0.05 and thus significant. Significant enrichment
was only found in TF-TF networks in case of motif no. 332. Network motif pictures are in Figure 3.
doi:10.1371/journal.pone.0080751.t005
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nodes as well. These may be key components in the metabolic-
inflammatory interplay in the pathomechanism of psoriasis.
‘‘Slow’’ positive feedback loops containing gene regulatory
interactions and ‘‘fast’’ loops containing only PPIs were also
found. All positive feedback loops had common nodes, thus a
merged network was generated containing interlinked slow and
fast positive feedback loops (Figure 4). Transcriptional changes of
all nodes and influence of all edges supported the sustainment of
lesional phenotype in this sub-network. Boolean analysis of the
resultant controller network was also performed. Nodes with
downregulated expression got value of 0 and nodes with
upregulated expression got value of 1. Future state of nodes was
set based on interactions (Table 6). The output boolean values
were the same as the input state values which prove the role of the
controller network in the sustainment of present (lesional)
phenotype. Chemical - protein interaction analysis further prove
the importance of controller network.
Analysis of chemical-protein interaction networks
Undirected and directed chemical-protein interaction networks
were constructed using STITCH database, which contains
interactions between proteins and chemical compounds (internal
Figure 4. Positive feedback loops and the merged controller sub-network in lesional psoriatic skin. Individual positive feedback loops
with 2, 3 or 4 nodes are shown. Node color is blue if the gene expression is decreased and red if increased. Merged controller sub-network is shown
on the top. Node color is proportional with fold change. red line: gene regulatory interaction; blue line: protein-protein interaction; arrow-headed
line: activation; bar-headed line: inhibition
doi:10.1371/journal.pone.0080751.g004
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non-protein substances, drugs and environmental substances).[19]
Drugs or potential drugs were filtered out from chemicals and
ranked by degree and stress centrality in case of undirected and
out degree centrality in case of directed networks (Table S4).
Top ranked drugs were grouped into Anatomical Therapeutic
Chemical (ATC) classes (Table 7).[43] KEGG DRUG was used
for classification.[44] Results show a big overlap between
undirected and directed network analysis. Best rated drugs
consisted of retinoic acid, cholecalciferol, costicosteroids, metho-
trexate, sirolimus and tacrolimus, which can be already found in
psoriasis guidelines and large clinical trials have proved their
effectiveness.[45]
Psoriasis studies are available for numerous potential drugs with
high centralities. ‘‘Blood glucose lowering drugs’’ are promising
drug candidates. The biguanide metformin is associated with
reduced psoriasis risk in a population based case control study.[46]
Many studies are available about ‘‘Thiazolidinedione’’ group. A
recent meta-analysis showed significant decrease in Psoriasis Area
and Severity Index (PASI) scores compared to placebo in case of
pioglitazone and non-significant improvement in PASI 50/70 in
case of rosiglitazone.[47] Troglitazone normalized histological
features in psoriasis models and the lesional phenotype in a small
clinical trial.[48] The ‘‘HMG CoA reductase inhibitor’’ drug
simvastatin was effective in a pilot study, although atorvastatin in
the same class showed only a non-significant improvement in a
different study.[49,50] Salicylic acid has antifungal effects and it’s
used as adjuvant because of its keratolytic effect in the treatment of
psoriasis.[51] The ‘‘Antineoplastic agent’’ methotrexate is a well-
known medication for psoriasis but several additional drugs in the
same class were found in our analysis. Studies are available about
5-fluorouracil for the treatment of dystrophic psoriatic fingernails,
but it showed only non-significant improvement.[52] Micellar
paclitaxel significantly improved psoriasis in a prospective phase II
study.[53] A study reported significant effectiveness of topical
caffeine.[54] ‘‘Calcium channel blocker’’ nifedipine is found to be
inductor of the disease in a case control study.[55] A study in 2005
reported significant PASI score reduction of 49.9% by topical
theophylline ointment.[56] Mahonia aquafolium extract - consist-
ing of berberine among others - is not classified into ATC classes,
but three clinical trials already indicated improvement of psoriasis
with this substance.[57] Multiple studies prove efficacy of the
terpenoid triptolide in the treatment of psoriasis.[58] A recent
study investigated effect of rifampicin on psoriasis and reported a
50.03% mean PASI reduction.[59] Study about the treatment of
psoriasis with curcumin was carried out but reported only low
response rate.[60]
In an in vitro experiment the ‘‘Lipid modifying agent’’
clofibrate, but not bezafibrate reversed UVB-light-mediated
expression of psoriasis – related inflammatory cytokines (interleu-
kin-6, interleukin-8).[61] Fluvastatin and pravastatin have the
potential to inhibit Th17 cell chemotaxis thus lowering immune
cell infiltration of psoriatic skin.[62] Anti-proliferative effect of
novel COX2 inhibitors on HaCaT keratinocytes was proven in an
in vitro experiment and possible therapeutic use in psoriasis was
supposed. However no such experiment was carried out with
celecoxib which was the only COX2 inhibitor in best rated
drugs.[63] N-acetyl-cysteine attenuated TNF alpha – induced
cytokine production in primary human keratinocytes, which
suggests its anti-psoriatic potential.[64] The ‘‘Thiazolidinedione’’
ciglitazone was never used as a medication, but inhibited
keratinocyte proliferation in a dose dependent fashion.[48]
Histone – deacetylase inhibitor trichostatin A blocked the
conversion of regulatory T cells to IL17 expressing T cells
suggesting its beneficial role in treating psoriasis.[65] Tse et al.
suppose that antiproliferative effect of arsenic compounds could
have positive effects on psoriatic skin.[66] The phosphodiesterase
inhibitor rolipram has the ability to block enterotoxin B-mediated
induction of skin homing receptor on T lymphocytes and may
have the potential to inhibit lymphocytic infiltration of lesional
skin.[67] The natural polyphenolic compound rottlerin is a potent
inhibitor of NFkB and may have disease modulating effects.[68]
Case reports are available about psoriasis induction by
clonidine, ‘‘agents acting on the renin-angiotensin system’’ like
captopril or losartan; the ‘‘protein kinase inhibitor’’ and
‘‘antineoplastic agent’’ imatinib; diclofenac, olanzapine, fluoxetine
and chloroquine. Also case reports are available about the
beneficial effects of ritonavir; ‘‘antineoplastic agents’’ like cytara-
bine, doxorubicin, and cysplatin; gefitinib, colchicine, lidocaine
and nicotine.[69–83]
Table 6. Boolean analysis of controller network.
Input state Relation Future state(*)
NFATC* = FOS 0 0 0
FOS* = EDN1 0 0 0
EDN1* = NFATC1 and INS-IGF2 and LEP 0 0 and 0 and 0 0
INS-IGF2* = PPARG and LEP 0 0 and 0 0
LEP* = EDN1 and INS-IGF2 0 0 and 0 0
PPARG* = INS-IGF2 and LEP and AR 0 0 and 0 and 0 0
AR* = not (IL8 and NFKB1) 0 not (1 and 1) 0
STAT3* = not AR 1 not 0 1
IRF1* = STAT3 1 1 1
IL8* = not PPARG; STAT3 and IRF1 and NFKB1 1 not 0; 1 and 1 and 1 1
IL1B* = CCL2 1 1 1
NFKB1* = not AR; IL1B 1 not 0; 1 1
CCL2* = NFKB1 and IL1B 1 1 and 1 1
Logical relations can be seen in the first and third column. Input and future state of network is stationary.
doi:10.1371/journal.pone.0080751.t006
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Table 7. Published Drugs.
ATC Class Drugs
STUDIES AVAILABLE
Retinoids for topical use in acne retinoic acid
Corticosteroids dexamethasone, hydrocortisone, corticosterone, prednisolone
H2 receptor antagonists cimetidine
Immunosupressants sirolimus, tacrolimus
Antiinflammatory and antirheumatic drugs indomethacin
Blood glucose lowering drugs excl. insulines metformin, troglitazone, rosiglitazone, pioglitazone
Intestinal anti-inflammatory agents sulfasalazine
Vitamins cholecalciferol, folic acid
Antimycobacterials rifampicin
Mineral supplements selenium
Antifungals for topical use salicylic acid
Antineoplastic agents 5-fluorouracil, methotrexate, paclitaxel, cycloheximide
Cardiac stimulants excl. cardiac glycosides epinephrine-bitartrate, norepinephrine
Lipid-modifying agents, plain simvastatin, atorvastatin-calcium
Calcium channel blockers nifedipine
Psychoanaleptics caffeine
Thyroid therapy Liothyronine
Drugs for obstructive airway diseases theophylline
N/A berberine, curcumin, triptolide
EXPERIMENTAL EVIDENCE
Topical products for joint and muscular pain capsaicin
Respiratory system N-acetyl-L-cysteine
Antineoplastic agents Velcade, celecoxib
Hormone antagonists and related agents tamoxifen
Cardiac stimulants excl. cardiac glycosides isoproterenol
Liver therapy glycyrrhizinic acid
Antiinfectives and antiseptics, excl. combinations with
corticosteroids
arsenic
Beta blocking agents propranolol
Lipid-modifying agents, plain clofibrate, bezafibrate, fluvastatin, pravastatin
Blood glucose lowering drugs excl. insulines ciglitazone
N/A N-ethylmaleimide, baicalein, apigenin, SB 202190, monensin, rolipram, eflornithine, calphostin C,
trichostatin A, rottlerin
CASE REPORTS
Antivirals for systemic use ritonavir
Antiinflammatory and antirheumatic drugs diclofenac, ibuprofen, aspirin
Antigout preparations colchicine
Antiprotozoals chloroquine
Ophtalmologicals atropine
Antineoplastic agents cytarabine-hydrochloride, doxorubicin, cysplatin, imatinib, docetaxel, gefitinib
Cardiac stimulants excl. cardiac glycosides phenylephrine
Antiadrenergic agents, centrally acting clonidine
Agents acting on the renin-angiotensin system captopril, losartan
Anaesthetics lidocaine
Psycholeptics olanzapine
Psychoanaleptics fluoxetine
Other nervous system drugs nicotine
doi:10.1371/journal.pone.0080751.t007
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The 32 effective drugs of ‘‘Studies available’’ group in Table 7
were filtered out from STITCH data and target proteins were
analyzed. All target proteins got an in-degree value reflecting the
number of effective drugs acting on it. The group of proteins
forming the controller sub-network was compared with the
remaining target proteins. The controller sub-network protein
group got significantly higher median value (10 vs. 1) using Mann-
Whitney Rank Sum Test than the other one, which prove the
importance of the controller sub-network in psoriatic lesions.
(Figure 5) (p,0.001; in-degree has power law distribution, thus T-
test could not be used) Higher median value could be caused by
higher original degree centralities of controller network proteins in
PPI networks, but only weak relation have been found between
original degree centrality and the number of effective drugs acting
on a protein, which cannot explain the big difference between the
median of two groups (corrected R square value in regression
analysis: 0.304)
In summary, studies are available for 34 drugs found by our
analysis, experimental evidence is available for 24 drugs, case
reports suggest beneficial or disease-inductor effect of 21 drugs and
98 unpublished drug candidates for the treatment of psoriasis were
also found (Table 7–8).
Discussion
Microarray Meta-analysis
Previous meta-analysis of psoriasis microarray studies was
carried out by Tian et al. 1120 DEGs were found using 5 studies
and 1832 DEGs using 3 studies.[84] We used the same 5 studies,
but samples with inadequate quality were excluded from each
study using arrayQualityMetrics package. The high number of
DEGs (5363) in our study may be surprising, but it can be caused
by the lower gene expression fold change cutoff (1.5 and 21.5
instead of 2 and 22). The pre - filtering process of samples can
decrease variance and can also increase the number of DEGs.
Further analysis of DEGs was carried out with Ingenuity Pathway
Analysis (IPA) by Tian et al. IPA uses published references, carry
out gene set enrichment analysis and TF detection. We used
fundamentally different analysis. We generated PPI networks
based on the largest PPI database (STRING) available which not
only contain experimentally proven interactions but highly reliable
interactions based on prediction algorithms or data mining. PDI
network was also generated using not only literally proven
interactions but interactions based on high fidelity prediction
algorithms. Using lower DEG fold-change cutoff and detailed
analysis based on node centrality statistics made it possible to
identify proteins yet not associated with the disease but may have
remarkable impact on pathogenesis. A chemical – protein
interaction network based on STITCH database was also created
and disease – modifying drug prediction was also possible with this
method.
Keratinocyte hyperproliferation and Psoriasis
Keratinocyte hyperproliferation and inhibition of apoptosis are
well-known phenomena in psoriasis. Several proteins have been
associated with these mechanisms like BCL2, BAX, NFATC1,
PPARd, EGF, mTOR, NF-kB etc.[85–88] Most of them were in
central proteins detected by DEG-derived network analysis.
Candidate DEG-coded proteins for hyperproliferation like
CCNA2, TFDP1 and MECOM were also found. CCNA2
encodes Cyclin A2, that controls S phase and G2/M transition.
Not only cell cycle progression is abnormal in lesional skin, but
actin cytoskeleton organization as well.[89] A recent study
reported that CCNA2 protein has role in cytoskeletal rearrange-
ments and cell migration as well.[31] Cyclin A2 may take part in
hyperproliferation and in aberrant actin cytoskeleton organization
in psoriatic skin keratinocytes. TFDP1 encodes DP1 protein which
is a dimerization partner of E2F transcription factor. The E2F/
DP1 heterodimers regulate cell cycle via DNA replication control
and apoptosis. DP1 has E2F-independent function as well: DP1
can stabilize Wnt-on and Wnt-off states in Wnt/b-catenin
signaling and determine differential cell fates.[37] TFDP1-
regulated genes belong to cell cycle progression as shown by
BinGO analysis (Table S5). TFDP1 also has a reciprocal gene
Figure 5. Effect of anti-psoriatic drugs on controller network. Higher number of effective anti-psoriatic drugs act on controller nodes than on
other proteins. Totally the targets of 32 effective anti-psoriatic drugs were analyzed (median 10 vs. 1) *p,0.001
doi:10.1371/journal.pone.0080751.g005
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expression regulation with AR. This interaction was responsible
for motif no. 332 enrichment in psoriasis PDI network compared
to complete PDI network. This interaction may connect the
hyperproliferation machinery to the merged controller sub-
network.
Immunological-metabolic interplay in psoriasis
Psoriasis is an immune-mediated disease. Some proteins which
are published as important factors in pathogenesis were absent
from DEGs in our microarray-meta analysis, such as TNF alpha,
which is an important target in psoriasis therapy. This could be
explained by the fact, that increased TNF alpha in psoriatic
plaques can be caused mainly by post-transcriptional mecha-
nisms.[90]
Many proteins published in association with the immunopatho-
genesis of psoriasis were highly ranked hubs in PPI networks: IL1,
IL8, TGFB1, SP1, STAT1, STAT3, NFKB1, IRF1 etc.[87,91–
97] A highly interconnected cluster mainly consisting of
upregulated chemokines and chemokine receptors was also found
by PPI analysis (Figure S3). The downregulation of src kinase FYN
seems to be a counteracting compensatory mechanism as this
protein is important in IFN gamma action, in TNF alpha induced
COX2 expression and in adipose tissue - mediated inflammation
leading to insulin resistance. These processes are important in the
pathomechanism of psoriasis.[32,98,99] These data suggest that
the FYN inhibitor KBio2_002303 may have beneficial effects in
the treatment of psoriasis. An important node in controller sub-
network is IL8. Although its role in psoriasis pathogenesis is
published, no trial has been done with IL8 inhibitors.[100] This is
true for CCL2 and IRF1 as well. Our study confirms their basic
role in sustainment of lesional phenotype. Both can be found in
highly ranked hubs and CCL2 is also essential in controller sub –
network by activating two positive feedback loops related to
inflammation.
Psoriasis and metabolic syndrome comorbidity is a well-known
phenomenon. There is a complicated interaction between the two
diseases mediated by inflammatory cytokines among others.[101]
Numerous DEG-coded proteins associated with both diseases
could be found in central proteins like PPARG, INS-IGF2, LEP
Table 8. Drug candidates unassociated with psoriasis.
ATC Class Drug
Retinoids for topical use in acne retinol
Blood glucose lowering drugs excl. insulines glyburide
Vitamin K and other hemostatics menadione
Antineoplastic agents aldophosphamide, MLS003389283, etoposide, dasatinib, decitabine
Sex hormones and modulators of the genital system (4–14c)pregn-4-ene-3,20-dione, mifepristone, testosterone-propionate, androstanolone,
diethylstilbestrol, raloxifene
Hormone antagonists and related agents flutamide, fulvestrant
Cardiac stimulants excl. cardiac glycosides bucladesine
Cardiac glycosides G-Strophantin
Drugs for obstructive airway diseases salbutamol
Antiadrenergic agents, centrally acting reserpine
Antiadrenergic agents, peripherally acting prazosin
Lipid modifying agents, plain lovastatin, pitavastatin, fenofibrate
Calcium channel blockers verapamil
Diuretics furosemide, spironolactone
Liver therapy silibinin
Platelet aggregation inhibitors excl. heparin dipyridamole, cilostazol, amiloride-hydrochloride
Agents acting on the renin-angiotensin system telmisartan, valsartan
Anaesthetics ketamine, propofol, cocaine, isoflurane
Analgesics morphine
Psycholeptics haloperidol, clozapine, diazepam
Psychoanaleptics desipramine, amitriptyline, metamphetamine
Antiepileptics phenobarbital, valproic acid
Antidotes naloxone
Other nervous system drugs carbacholin
N/A cytochalasin D, aminoguanidine, Neurogard, paraquat, Y27632, oxidopamine, nitroarginine,
AC1LA4H9, SL327, emodin, 2,3,7,8-tetrachlorodibenzo-dioxin, 3-(2-aminoethyl)-5-[(4-
ethoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione, CHEMBL248238, geldanamycin, anisomycin,
8-bromocyclic GMP, tempol, MK-801, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, ionomycin,
herbimycin, pyrrolidine dithiocarbamate, nordihydroguaiaretic acid, gamma-imino-ATP, forskolin,
GMP-Pnp, roscovitine, flavopiridol, N-formyl-Met-Leu-Phe, ns-398, sodium butyrate, AC1L1I8V,
tyrphostin B42, kainic acid, pirinixic acid, IBMX, bisindolmaleimide I, proline-dithiocarbamate,
KBio2_002303, Zillal, thapsigargin, calcimycin, clenbuterol, indole-3-carbinol, 1,9-pyrazoloanthrone,
herbimycin, kaempferol, daidzein, lithium-chloride, naringenin
doi:10.1371/journal.pone.0080751.t008
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etc.[102–104] Others, like PIK3R1, AR and MEF2A may have
role in the development of metabolic syndrome in psoriasis.
PI3KR1 is important in the development of insulin resistance, it
propagates inflammatory response in obese mice and may be an
important link between the obesity-inflammation interplay in
psoriasis.[33] AR has important effect on insulin signaling and
thus insulin resistance. It is published that AR knockout mice
exhibit insulin resistance.[35] To our knowledge AR has not yet
been associated with psoriasis. However it was found in 1981, that
lower serum testosterone level therefore decreased AR activation
can be detected in psoriatic patients.[105] AR and PPARG
connect inflammation- and metabolism-related hubs in controller
network thus modulation of these proteins can be beneficial in
psoriatic patients, which was also proven by our drug target
analysis (Figure 5). MEF2A is important for GLUT4 expression on
insulin-responsive cells. Expression of MEF2A is downregulated in
lesional skin samples which suggests a possible mechanism for
insulin resistance in psoriasis.
Many drugs, which are already widely used as treatment for
psoriasis could be found in highly ranked nodes of chemical-
protein interaction networks such as methotrexate, retinoic acid,
corticosteroids, sirolimus and tacrolimus. According to STITCH
data all of them act through at least one of the hubs in controller
sub-network. Top ranked ATC drug classes target members of
controller sub-network as well. Blood glucose-lowering drugs act
through PPARG and INS-IGF2 activation, which can be the basis
of the positive effects of fibrate and HMG-CoA inhibitors in
psoriasis as well.[47] Cardiac stimulants such as adrenergic agents
also have high impact on lesional skin’s PPI and PDI network,
mainly by modulating hubs in controller sub-network. ‘‘Sex
hormones and modulators of the genital system’’ ATC drug class
act on AR. The ‘‘antineoplastic drug’’ methotrexate mainly acts
through the accumulation of adenosine, but other antineoplastic
agents may have their effect on keratinocyte hyperprolifera-
tion.[106] Studies or case reports already suggest efficacy of some
antineoplastic drugs but several new possible agents were found in
our analysis.[53,107,108] Mental stress is a known trigger for
psoriasis and connection between the neuroendocrine system and
skin immune system has been reported. [3,109] This is not
surprising that numerous drugs acting on the CNS are enriched in
highly ranked drugs. A lot of other drugs which are either classified
in ATC classes or just drug candidates are found like kainic acid,
cocaine, the HDAC inhibitor sodium butyrate, the PKC inhibitor
bisindolylmaleimide I etc. (Table 7)
In summary this is the first time PPI, PDI and chemical-protein
interaction networks of psoriatic skin samples has been examined
with detailed network analysis. Network-building DEGs were
identified with fine-quality microarray meta-analysis of 187 non-
lesional and 189 lesional samples. Several proteins were found
which are yet not associated with psoriasis but may have high
impact on the pathogenesis of the disease. Basic disease controller
sub-network was also constructed consisting of central nodes coded
by DEGs. Numerous anti-psoriatic drugs and drug candidates
were also found acting mainly on these nodes.
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